Nasal Antisepsis for C. Auris Prevention

Description

This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.

Conditions

Candida Auris Infection, Colonization, Asymptomatic

Study Overview

Study Details

Study overview

This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.

Impact of Nasal Antisepsis on Candida Auris Colonization

Nasal Antisepsis for C. Auris Prevention

Condition
Candida Auris Infection
Intervention / Treatment

-

Contacts and Locations

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 60612

Chicago

RML Specialty Hospital, Chicago, Illinois, United States, 60624

Hinsdale

RML Specialty Hospital, Hinsdale, Illinois, United States, 60521

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * History of C. auris colonization or infection
  • * Patient in a participating facility
  • * History of severe allergy to iodine-based products, defined as anaphylaxis or rash
  • * Currently breastfeeding or pregnant
  • * Non-English language speaking

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mary K Hayden,

Mary K. Hayden, MD, PRINCIPAL_INVESTIGATOR, Rush University Medical Center

Study Record Dates

2028-12